Two Feng Zhang lab alumni find a new CRISPR enzyme that could take a Big Gulp out of RNA — and a raft of devastating diseases

Jason Mast

Editor

MIT buddy biologists Omar Abudayyeh and Jon Gootenberg were sitting in the Quebec Convention Center at the annual CRISPR conference in 2019 when, buried in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Two Feng Zhang lab alumni find a new CRISPR enzyme that could take a Big Gulp out of RNA — and a raft of devastating diseases

Jason Mast

Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Two Feng Zhang lab alum­ni find a new CRISPR en­zyme that could take a Big Gulp out of RNA — and a raft of dev­as­tat­ing dis­eases

Jason Mast

Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Two Feng Zhang lab alumni find a new CRISPR enzyme that could take a Big Gulp out of RNA — and a raft of devastating diseases

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra